MD Anderson connects devices to EMRs; Health system predicts knee surgery outcome;

@FierceMedDev: ICYMI yesterday: Samsung, Welch Allyn back $20M round for contact-free monitoring startup EarlySense. Article | Follow @FierceMedDev

@VarunSaxena2: Bill introduced in Congress to simplify marketing of 'research use only' devices and diagnostics. Story | Follow @VarunSaxena2

@EmilyWFierce: Abbott Labs continues Dx winning streak with bladder cancer biomarker deal. Article | Follow @EmilyWFierce

> MD Anderson Cancer Center will use the SmartLinx Medical Device Information System from Capsule Tech to integrate medical device data into the hospital's electronic medical record system (EMR). The SmartLinx will use two mobile clinical computers to integrate data form more than 2,000 medical devices across 650 patient beds, eliminating the need for manual data entry. Release

> The Dartmouth-Hitchcock health system is working with software giant SAP to help predict surgical outcomes for patients with chronic knee pain. Dubbed GreenCare, the system aims to provide real-time data analytics to allow physicians to better inform a patient of the potential outcome for knee surgery. Release

> Researchers at the North Carolina State University have developed wearable, multifunction sensors using silver nanowires that could have applications in wearables and prosthetics. Release

Biotech News

@FierceBiotech: First on Fierce: Eyeing an IPO, Zymeworks partners up with Celgene on bispecifics. Report | Follow @FierceBiotech

@JohnCFierce: Gene therapy pioneer ReGenX fuels R&D, hiring spree with $30M VC round. Article | Follow @JohnCFierce

@DamianFierce: "Precision medicine" about to get stuffed into 100K bio PRs. "Our precision medicine immunotherapy, with applications in NASH and Ebola ..." | Follow @DamianFierce

> Actavis and the future of discovery-averse 'growth pharma.' More

> Scandal-plagued Salix said to consider a sale. Item

Pharma News

@FiercePharma: Law firms trolling for shareholders to sue Sanofi over alleged kickbacks. News | Follow @FiercePharma

@CarlyHFierce: Depomed drawing on digital savvy--and 250 reps--to relaunch Nucynta franchise. Story | Follow @CarlyHFierce

> Actavis CEO: Pharma believer and Botox user, yes. The Borg? No. More

> Salix Pharmaceuticals eyeing sale in wake of corporate fallout. Article

Drug Delivery News

> Celator's delivery platform results in FDA's fast-track designation for its cancer candidate. Report

> U. Arizona team looks to bring GI delivery vehicle to market. More

> 'Micromotors' made of zinc and polymer actively release drugs at stomach lining. Story

> BD must still pay $350M+ due to safety syringe spat; other punishments delayed pending appeal. Article

> India's Piramal to buy U.S. maker of sterile injectables, antibody drug conjugates. News

Diagnostics News

> Abbott Labs continues Dx winning streak with bladder cancer biomarker deal. More

> SV Bio changes name to Lifecode, plans rollout of NGS cancer assay. Story

> Protein analysis method could act as new cancer biomarker. More

> DNA Electronics snags nanoMR for $24M to gain ground in sepsis market. Story

> GenomeDx expands prostate cancer Dx reach with Medicare coverage deal. Article

Pharma Marketing News

> Depomed drawing on digital savvy--and 250 reps--to relaunch Nucynta franchise. Story

> Embattled Salix hires bankers to weigh a potential sale. More

> J&J eyes long-acting boost for Invega franchise with quick FDA look at new formula. Report

> Lilly snares formulary spots for diabetes meds, no pricing war necessary. Story

> Eisai's copay offer on Belviq has unintended consequences for Arena. Article

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.